Infection with Borrelia burgdorferi, the etiologic agent of Lyme disease, is associated with an early and dominant humoral response to the spirochete's 23-kDa outer surface protein C (OspC). We have cloned and expressed OspC as a fusion protein in Escherichia coli and have shown that patient serum samples react with it in an enzyme-linked immunosorbent assay (ELISA) (S. J. Padula, A. Sampieri, F. Dias, A. Szczepanski, and R. W. Ryan, Infect. Immun. 61:5097-5105, 1993). Now we have compared the detection ofB. burgdorieri-specific immunoglobulin M antibodies in 74 individuals with culture-positive erythema migrans by a whole-cell ELISA, immunoblot, and the recombinant OspC (rOspC) ELISA. Seventy-six negative controls were also studied. With all of the tests, there was a statistically significant association between the duration of disease and the frequency of a positive result. With the rOspC ELISA, the predictive value of a positive test was 100%6 and the predictive value of a negative test was 74%. Similar results were obtained with the whole-cell ELISA and with the immunoblot using as the source of test antigen a strain of B. burgdorferi which expresses abundant levels of OspC. We conclude that the use of rOspC in an ELISA is a convenient, readily automated, and easily standardized test for the serodiagnosis of early Lyme disease.
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Lyme disease is a multisystemic illness caused by the tickborne spirochete Borrelia burgdorferi (4, 7, 26) . Early manifestations of the infection include an expanding, erythematous rash at the site of the tick bite, called erythema migrans (EM), and a nonspecific flu-like illness (25) . Recognition of the distinctive EM rash is important, as prompt treatment with appropriate antibiotics usually prevents the late sequelae of neurologic, cardiac, or musculoskeletal organ involvement (27) . EM, however, may not be recognized in some cases of Lyme disease (25) . Failure by the patient to recognize the rash, an atypical appearance of the rash, and possibly the lack of development of a skin lesion may account for the variable recognition of EM in patients with Lyme disease.
In patients without recognized EM but suspected of having Lyme disease, establishment of the diagnosis is usually dependent on serologic confirmation of exposure to B. burgdorferi.
Accurate serodiagnosis, however, has been complicated by delayed humoral response after infection and by antibodies to other bacteria which cross-react with proteins from B. burgdorfen (19, 24) . Both the lack of standardization of antigen preparations used for testing and nonconformity in interpretation of results have also contributed to the confusion surrounding the serodiagnosis of this disease (15) .
Using immunoblots of lysates from B. burgdorferi 2591, we found predominant immunoglobulin M (IgM) reactivity to a 23-kDa protein in serum samples from patients with early Lyme disease (10, 20) . We cloned and sequenced the gene encoding this protein and found that it is OspC, an outer surface protein (20) . We expressed recombinant OspC (rOspC) as a fusion protein in Escherichia coli and showed that serum samples from patients with Lyme disease react in an enzyme-linked immunosorbent assay (ELISA) with rOspC (20) . In the present study, we compared the detection of B.
burgdorferi-specific IgM antibodies in patients with culturepositive EM by a whole-cell (WC) ELISA, immunoblot, and the rOspC ELISA. (2) . The spirochetes were grown in BSK II medium in a closed flask at 33°C for 10 to 14 days as previously described (3) . The gene encoding OspC was cloned from B. burgdorferi 2591 as previously described (20) . rOspC was expressed as a fusion protein with glutathione S-transferase at the amino terminus to facilitate its purification from E. coli proteins as previously described (20) For all three methods of testing, there was a statistically significant association between longer disease duration and greater frequency of a positive test (Table 5 ). There was no relationship seen between the results of serologic testing and There were no group 2 serum samples which were positive by IgG immunoblot or IgG WC ELISA, including the two samples found to be positive by IgM immunoblots.
MATERIALS AND METHODS

Study
In Table 6 , predictive values of the different serologic tests as determined by the results obtained with the 74 Lyme disease serum samples and the 76 negative serum controls are compared. The results of the immunoblot analysis using three different criteria for a positive test are presented. There were only two Lyme disease samples which did not bind the 23-kDa antigen, but they still fulfilled one of the criteria for a positive blot by binding three or more bands. There was only one example among the Lyme disease culture-positive serum samples of binding to the 23-kDa protein but not binding three or more bands. Because of these infrequent findings, there was no essential difference in the sensitivities of the IgM blots with three different criteria for a positive assay. There was, however, a significant drop-off in specificity when binding of the 23-kDa protein was used as the sole criterion for a positive immunoblot. This reflects the relatively frequent observation of binding to the 23-kDa antigen (usually faintly) among the negative serum controls. In contrast, there were no false-positive results with the WC and rOspC ELISAs. A positive result by either of these two methods, both of which contain OspC, was therefore superior to a positive result by immunoblot, using the positive criterion of binding to the 23-kDa protein, for accurately predicting the presence of disease. The predictive value of a negative result was essentially equivalent for all three methods.
DISCUSSION
Diagnosis of Lyme disease in patients with early disease who present with distinctive EM is usually not a problem. However, in a significant number of patients, EM may not be recognized and the only manifestation of infection may be nonspecific constitutional complaints. In these patients, serodiagnosis can play an important role in confirming the disease and leading to prompt and appropriate antibiotic treatment. Accurate serodiagnosis for early Lyme disease, however, has been complicated by delayed humoral response to the infection and by the fact that antibodies to other bacteria cross-react with proteins from B. burgdorferi (19, 24 (5, 8, 13, 17, 21) . This approach was prompted by initial immunoblot studies with B. burgdorfeni lysates in which an early and predominant IgM antibody response to the flagellar protein was demonstrated (9) . Use of flagellar protein-based serologic tests may be problematic, however, because of the relatively frequent finding of cross-reactive antibodies to conserved flagellar epitopes from commonly occurring commensal and pathogenic spirochetes, such as those found in the mouth (19, 22) .
We and others have recently described another early and dominant antibody response in patients with Lyme disease which is directed to a protein of approximately 23 kDa (1, 11, 20) . European investigators had previously described an immunodominant, early antigen of similar molecular mass called pC (12, 29, 30) . These early targets of the immune response have now been determined to be OspC, a protein located in the outer membrane of the spirochete (12, 20, 28) . Interestingly, stained gels of only a small percentage of lysates of strains of North American B. burgdorferi have revealed a major protein with the apparent molecular mass of OspC (29, 30) . Included among the OspC-negative strains is B31, a widely distributed strain which is used as the source of test antigen in many clinical laboratories. Reasons for the variability in expression of OspC by these strains, which have been passaged for multiple generations in vitro, may be due to mutation, loss of the plasmid encoding the gene, or another as yet undefined mechanism(s) which is sensitive to varying growth conditions (20, 23, 28) . The high prevalence of OspC-negative, in vitropassaged strains probably accounts for the heretofore unappreciated reactivity of serum samples from patients with early Lyme disease with OspC. Nevertheless, frequent reactivity against OspC observed in serum samples from infected patients clearly argues that disease-causing spirochetes express OspC and that it is a dominant target of the early humoral immune response.
We have cloned and expressed OspC as a fusion protein in E. coli (20) . In a previous study, we tested the feasibility of using rOspC in an ELISA for detection of Lyme disease (20) . We showed that 15 of 15 serum samples from patients with clinically suspected Lyme disease had positive immunoblots and were also strongly reactive with rOspC. We also found that 5 serum samples from patients with syphilis, 10 containing rheumatoid factor with a high titer, 5 from patients with Epstein-Barr virus infection, and 10 from patients with systemic lupus erythematosus with antinuclear antibodies with high titers were all negative for anti-rOspC.
On the basis of those results, we have now carried out studies on a large panel of serum samples obtained from patients with culture-positive EM as well as a control group including patients from an area where Lyme disease is not endemic and patients with severe periodontitis.
As shown in Table 5 , there was a positive correlation between duration after EM onset and frequency of positive results, regardless of the assay used. For the entire group of Lyme disease serum samples, the sensitivities of the immunoblot, regardless of the criterion used for a positive result, and the rOspC ELISA were equivalent (approximately 65%) and slightly better than that of the WC ELISA (58%) ( Table 6 ). The specificities of all three tests, including the immunoblot with the criterion of three or more bands with or without the 23-kDa band, were 100% or nearly so (Table 6) .
It There were a number of serum samples in which there was a discrepancy between the observed reactivity to the 23-kDa protein by immunoblot and the rOspC ELISA. In most of these cases, including the negative controls from Iceland, there was faint reactivity found by immunoblot and negative reactivity by rOspC ELISA. This finding highlights the potential confusion introduced by subjective interpretation of intensity and apparent molecular size of a band on an immunoblot. Explanation of the less frequent situation of reactivity to rOspC and no band seen on the immunoblot (e.g., patient 6) is more difficult. Although strain 2591 served as the source of both the antigen used for the immunoblots and the gene used for expression of rOspC, there may be some differences in the expressed epitopes. For example, the rOspC is expressed as a fusion protein and coexpression of the glutathione S-transferase may influence the availability of immunoreactive sites. In addition, there is evidence that OspC is a lipoprotein in its native form, whereas rOspC likely lacks posttranslational modification (6, 12) . Immunoblotting of serum samples with the rOspC preparation has not revealed reactivity with a contaminating protein derived from E. coli (data not shown).
Another consideration in this study was whether the rOspC from strain 2591, originally isolated in Connecticut, would be a useful target for testing serum The results of this study suggest that the use of rOspC in an ELISA is a convenient, readily automated, and easily standardized test for the serodiagnosis of early Lyme disease. The rOspC assay compared favorably in sensitivity and specificity to the much more difficult and labor-intensive immunoblot using a lysate of a strain which produces abundant levels of OspC.
